- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
GoodRx Expands Access to Eli Lilly's New Diabetes Medications
The healthcare technology company partners with the pharmaceutical giant to offer discounted prices on two new oral GLP-1 drugs.
Apr. 9, 2026 at 1:44pm
Got story updates? Submit your updates here. ›
A new partnership aims to make cutting-edge diabetes treatments more accessible and affordable for patients.Santa Monica TodayGoodRx, a leading healthcare technology company, has announced a partnership with Eli Lilly and Company to expand access to two of the pharmaceutical giant's new oral GLP-1 medications, Foundayo™ and Zepbound® KwikPen®, for the treatment of type 2 diabetes.
Why it matters
This partnership aims to make these innovative diabetes treatments more affordable and accessible to patients, addressing a critical need in the healthcare system. GoodRx's platform allows users to compare prices and find discounts on prescription drugs, which can help improve medication adherence and overall health outcomes.
The details
Under the agreement, GoodRx will offer discounted prices on Foundayo and Zepbound KwikPen, two of Eli Lilly's newest oral GLP-1 receptor agonist medications for the treatment of type 2 diabetes. GLP-1 drugs work by stimulating the production of insulin, which helps regulate blood sugar levels. The partnership will provide patients with access to these new therapies at reduced out-of-pocket costs, potentially improving their ability to manage their condition.
- The partnership was announced on April 9, 2026.
The players
GoodRx
A leading healthcare technology company that provides price comparison and discount information for prescription drugs.
Eli Lilly and Company
A global pharmaceutical company that develops and manufactures innovative medicines, including the new oral GLP-1 drugs Foundayo and Zepbound KwikPen.
What they’re saying
“We're excited to partner with Eli Lilly to help make their new oral GLP-1 medications more accessible and affordable for patients. This aligns with our mission to provide consumers with the information and tools they need to make informed healthcare decisions.”
— Doug Hirsch, Co-CEO of GoodRx
“Expanding access to our latest diabetes treatments is a priority for Lilly. By working with GoodRx, we can reach more patients and help them manage their condition effectively.”
— David A. Ricks, Chairman and CEO of Eli Lilly and Company
What’s next
The partnership between GoodRx and Eli Lilly is expected to go into effect immediately, with the discounted prices on Foundayo and Zepbound KwikPen available to GoodRx users starting on April 15, 2026.
The takeaway
This collaboration between a leading healthcare technology company and a major pharmaceutical firm demonstrates a commitment to improving access and affordability of innovative diabetes treatments, which can have a significant impact on patient outcomes and quality of life.
